Abstract
Although surgical resection provides the only potentially curative modality in patients with pancreatic cancer, the long-term results of pancreatectomy still remain extremely poor. Despite the recent advances made in surgical techniques and/or increased surgical radicality, only limited progress has been made in improving the survival. Moreover, pancreatic cancer in most patients is surgically unresectable at the time of diagnosis. Chemotherapy and/or radiotherapy, therefore, still remain key modalities for treatment of pancreatic cancer. Recently, several randomized trials on the effects of these modalities have been reported. Various newly designed large-scale clinical trials are now in progress. In this article, recent important insights into the surgical treatment, chemotherapy, and radiotherapy of pancreatic cancer are discussed.
MeSH terms
-
Antimetabolites, Antineoplastic / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cisplatin / administration & dosage
-
Combined Modality Therapy
-
Deoxycytidine / administration & dosage*
-
Deoxycytidine / analogs & derivatives*
-
Drug Combinations
-
Gemcitabine
-
Humans
-
Intraoperative Care
-
Lymph Node Excision
-
Lymphatic Metastasis
-
Oxonic Acid / administration & dosage
-
Pancreatectomy* / mortality
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / mortality
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / radiotherapy*
-
Pancreatic Neoplasms / surgery
-
Pancreaticoduodenectomy
-
Pyridines / administration & dosage
-
Randomized Controlled Trials as Topic
-
Survival Rate
-
Tegafur / administration & dosage
-
Treatment Outcome
Substances
-
Antimetabolites, Antineoplastic
-
Drug Combinations
-
Pyridines
-
Deoxycytidine
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid
-
Cisplatin
-
Gemcitabine